Navigation Links
Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35)

Evelyn McGown, Ph.D. and Anna Lam, B.S.
Molecular Devices Corporation, 8/99


INTRODUCTION
Modern assays for proteolytic activity typically use synthetic chromogenic or flu-orogenic peptide substrates. Enzyme selectivity is obtained by choosing a peptide sequence uniquely recognized by the catalytic site of a particular enzyme. The chromophore or fluorophore is attached near the peptides cleavage site and enzymatic activity is detected by the increase in color or fluorescence. Chromogenic assays are easy in that one simply monitors the rise in absorbance above a (usually) low background. Fluorometric assays are much more sensitive than chromogenic assays, but are less straightforward. The substrate itself can be fluorescent, causing a high background. If the absorption spectra of the substrate and product overlap, the substrate can quench the signal from the product by absorbing either excitation or emission light. Therefore, both the excitation and emission wavelengths should be optimized to minimize interference from the substrate, while maintaining sufficiently high product fluorescence. This application note describes how to optimize a protease assay in the SPECTRAmax GEMINI micro-plate spectrofluorometer. We chose to use the protease caspase3 and a fluorogenic peptide substrate containing a coumarin derivative.

Coumarin derivatives are among the most popular fluorophores for peptide based protease assays because they are more sensitive and more watersoluble than other fluorescent derivatives.13 A 7amino4methylcoumarin (AMC) derivative was first used as a substrate for chymotrypsin1. Since then, AMC and the 7amino4trifluoromethylcoumarin (AFC) fluorophores have been used for various protease assays.14 In each case, cleavage of the fluorophore results in increased fluorescence, with a shift of excitation and emission maxima to longer wavelengths. AMC a
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
2. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
3. Using Validated siRNAs in Functional Genomic Assays
4. Nuclease Protection Assays: The Basics
5. Selection of Standards for Bio-Plex Cytokine Assays, Rev A
6. Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays
7. The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B
8. The iCycler iQ Detection System for TaqMan Assays, Rev B
9. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
10. Caspase-3 Activation - An Indicator of Apoptosis in Image-Based Assays
11. Amplification Efficiency of TaqMan Gene Expression Assays
Post Your Comments:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Cynosure, Inc. (NASDAQ: CYNO ) today announced financial ... Revenues for the first quarter of 2011 increased 16 percent ... 2010.   Net loss for the first quarter of 2011 was ... a net loss of $2.8 million, or $0.22 per basic and ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... The net income for the first quarter ended ... loss of $14.1 million during the same period in 2010. ... was related primarily to the $34.2 million in collaboration revenue ...
... VIVUS, Inc. (Nasdaq: VVUS ), a ... products, today reported its financial results for the first quarter ended ... quarter ended March 31, 2011, VIVUS reported a net loss of ... loss of $18.8 million or $0.23 per share for the first ...
Cached Biology Technology:Cynosure Reports Financial Results for the First Quarter of 2011 2Cynosure Reports Financial Results for the First Quarter of 2011 3Cynosure Reports Financial Results for the First Quarter of 2011 4Cynosure Reports Financial Results for the First Quarter of 2011 5Cynosure Reports Financial Results for the First Quarter of 2011 6MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... of years ago are recorded at daily rate in ... X-ray microscope has revealed growth bands in plankton shells ... The results could allow scientists to chart short ... years ago. Plankton shells show features like tree ...
... available in German . ... loss of eye lashes and eye brows, susceptibility to infection ... lengthy. Many cancer patients suffer from the intense effects that ... subcutaneously or administered intravenously to halt the growth of tumors ...
... salvia magnesium acetate, is a phenolic acid compound ... of caffeic acid. Salvianolic acid B exerts strong ... improves energy metabolism against cerebral ischemia-reperfusion injuries. Dr. ... Xiangya Hospital, Central South University, China found that ...
Cached Biology News:Reading ancient climate from plankton shells 2Nano-dwarves turn tumor assassins 2Nano-dwarves turn tumor assassins 3
... from 2 mM sodium phosphate buffer, pH ... D is a major lysosomal aspartyl protease ... kDa proenzyme. Overexpression of cathepsin D in ... risk of relapse and metastasis. Cathepsin D ...
Acetate Plate Sealers 100/Box...
...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
Biology Products: